Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China
Rituximab in thrombotic primary antiphospholipid syndrome: a pilot study from a single centre in China
复制标题
利妥昔单抗治疗血栓性原发性抗磷脂综合征:中国单中心的初步研究
DOI:
10.1136/annrheumdis-2020-219303
复制
发表时间:
2021-01
影响因子:
27.4
通讯作者:
Ye Junna
中科院分区:
文献类型:
--
作者:
You Yijun;Shi Ce;Zhou Zhuochao;Wang Fan;Sun Yue;Teng Jialin;Liu Honglei;Cheng Xiaobing;Su Yutong;Shi Hui;Yang Chengde;Ye Junna
Antiphospholipid syndrome (APS) is a multisystem disorder defined by a combination of arterial and/or venous thrombosis, recurrent fetal loss in women and persistent presence of antiphospholipid (aPL) antibodies such as lupus anticoagulant (LAC), anti-β2g
登录
查看更多内容
影响因子:
27.4
作者:
Ioannou, Y.;Lambrianides, A.;Isenberg, D. A.
通讯作者:
Isenberg, D. A.
影响因子:
6.2
作者:
Alijotas-Reig, Jaume;Garrido-Gimenez, Carmen
通讯作者:
Garrido-Gimenez, Carmen
影响因子:
1.1
作者:
Aakjær S;Bendstrup E;Ivarsen P;Madsen LB
通讯作者:
Madsen LB
影响因子:
2.6
作者:
Tse, J. R.;Schwab, K. E.;Simon, W.
通讯作者:
Simon, W.
影响因子:
--
作者:
R. Reece;J. Cañete;W. Parsons;P. Emery;D. Veale
通讯作者:
R. Reece;J. Cañete;W. Parsons;P. Emery;D. Veale